Istaroxime treatment significantly improved systolic blood pressure as well as cardiac output and renal function without increasing heart rate or...
CARMEL, Ind., Sept. 30, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ: MBX), a clinical-stage biopharmaceutical company focused on the...
Published data from two Phase 3 clinical trials demonstrated rapid reversal of pharmacologically-induced mydriasis with favorable safety profileFARMINGTON HILLS, Mich.,...
CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled...
CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing...
Casitas B-lineage lymphoma b (Cbl/b) is an E3 ubiquitin ligase that has been shown to be a key regulator of...
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company...
SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today...
DURHAM, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract...
CNP-104 demonstrated potential efficacy across multiple immunological and clinical measurements, supporting its continued development as the first disease-modifying treatment for...
SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Adaptive Research, a clinical trial site organization whose mission is to democratize...
Multidisciplinary board members bring expertise in drug discovery, clinical development, computational life science, GPCRs and drug formulationBOSTON, Sept. 30, 2024...
Patients with MASH/NASH treated with Rezdiffra experienced clinically meaningful and statistically significant improvements in emotional well-being and health distressStudy results...
– Company is aligned with the FDA on next steps for a 351(k) regulatory pathway to approval for ABP-450 (prabotulinumtoxinA)...
SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late...
- Study exceeded target enrollment, with an expected topline data readout from the interim analysis expected in 2025 - BridgeBio...
IMPACT trial is evaluating the safety and efficacy of pemvidutide in approximately 190 subjects with MASH; top-line efficacy data expected...
MELBOURNE, Australia and PRINCETON, N.J., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage...
Clinical data demonstrated treatment with AGA2118 resulted in dose-dependent increases in bone mineral densityWOODLAND HILLS, Calif., Sept. 30, 2024 (GLOBE...
Ratutrelvir was well-tolerated for 10 days and achieved consistent plasma levels in the predicted therapeutic window, without the need for...